The objective is to achieve capital growth on a medium to long-term basis.
Name | % Net Assets |
---|---|
CF Walker Crips UK High Alpha Acc | 8.5% |
Close Enhanced Commodities | 7.5% |
Allian z RCM BRIC Stars C Acc | 7.0% |
AXA Framlington UK Growth Acc | 5.5% |
Schroders Strategic Bond A Inc | 5.3% |
AXA Framlington Biotech Fu nd Acc | 4.8% |
GlaxoSmithKline | 4.7% |
BP | 4.4% |
Barcap S&P Note 2 4/11/2009 6% | 3.8% |
BG Group | 3.3% |
Key | % Net Assets |
---|---|
CF Walker Crips UK High Alpha Acc | 8.5% |
Close Enhanced Commodities | 7.5% |
Allian z RCM BRIC Stars C Acc | 7.0% |
AXA Framlington UK Growth Acc | 5.5% |
Other | 71.5% |
Date | n/a |
---|---|
Bid | 0.00 |
Offer | 0.00 |
Currency | n/a |
Change | 0.00 |
% | n/a |
YTD change | 0.00 |
YTD % | n/a |
Fund Inception | 31/01/2004 |
---|---|
Fund Manager | Tony Yousefian |
TER | 1.58 (10-Jul-2012) |
Minimum Investment | |
---|---|
Initial | 1000 |
Additional | 500 |
Savings | 50 |
Charges | |
---|---|
Initial | 3.75% |
Annual Mang't | 1.29% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.02 |
Sharpe ratio | 0.07 |
You are here: research